Infliximab [[electronic resource] ] : pharmacology, uses and limitations / / Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors

• Record Nr.: UNINA9910779511503321
• Pubbl/distr/stampa: New York, : Nova Science Publishers, c2012
• ISBN: 1-61942-345-6
• Descrizione fisica: 1 online resource (204 p.)
• Collana: Immunology and immune system disorders
• Altri autori (Persone): Fajardo GaitanMontserrat; Medrano AcevedoAntonio D
• Disciplina: 615.7/94
• Soggetti: Anti-inflammatory agents; Infliximab - Therapeutic use; Infliximab
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections""; ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohnâ€?s Disease ""; ""Fistulizing Crohnâ€?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing ""; ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ; ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics""; ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""; ""4.8. Neurological Events ""